Inhalation Route Toxicology: Challenges in Dose Uniformity and Respiratory Histopathology
Inhalation toxicology is essential for evaluating the safety of compounds delivered via respiratory exposure, whether intentionally (e.g., inhaled drugs) or incidentally (e.g., aerosols, industrial particulates). The design and interpretation of inhalation studies present unique challenges compared to oral or parenteral routes, particularly with respect to dose uniformity, particle size, and deposition patterns throughout the respiratory tract.
Generating a stable and reproducible aerosol is fundamental. The aerodynamic particle size distribution determines where deposition occurs—larger particles tend to settle in the nasopharyngeal region, while respirable particles (<5 μm) reach the bronchioles and alveoli. Uniformity of exposure across animals is influenced by chamber design (nose-only vs. whole-body), animal position, breathing patterns, and flow rate. Real-time aerosol monitoring is used to ensure consistency of concentration and particle size over the duration of exposure.
Histopathological evaluation of respiratory tissues—nasal passages, trachea, lungs—requires careful sectioning at predefined levels, as lesions may be localized. Inflammatory responses, epithelial hyperplasia, goblet cell metaplasia, and alveolar macrophage accumulation are among the typical findings. For toxicants that target deep lung structures, evaluating bronchioalveolar lavage (BAL) fluid provides insight into immune cell recruitment, protein leakage, and cytotoxicity.
Interpreting inhalation toxicity data also requires knowledge of species-specific respiratory anatomy and physiology. For example, rodents have a higher nasal airflow fraction, which can result in increased nasal deposition compared to humans. These differences must be accounted for when extrapolating findings to human risk, especially in IND filings for inhaled pharmaceuticals.